Novel geneticfactors contribute to Parkinson's risk northwesternu
Investigators have discovered novel genetic factors that contribute to the risk of Parkinson's disease, according to a Northwestern Medicine study published in the journalThe findings reveal novel short tandem repeat sequences within DNA in four distinct regions that are independent from currently known Parkinson's risk variants, of which may serve as novel therapeutic targets.
Parkinson's disease is heavily influenced by genetic factors, and more than 90 genetic variants are known to increase one's risk of developing Parkinson's disease. However, these variants account for less than half of all knownIn particular, short tandem repeats—short sequences of DNA repeated many times next to each other—have been suspected to contribute to the heritability of Parkinson's disease but have remained understudied due to a lack of efficient analysis methods.
This detailed analysis identified 34 novel genetic variants, 88% of which are located nearby variants previously known to increase Parkinson's disease risk. However, the investigators did discover novel short tandem repeats near four genes unknown to contribute to Parkinson's disease risk: NDUFAF2, TRIML2, MIRNA-129-1 and NCOR1.
"These independent short tandem repeats will be used as candidates for further functional follow-up studies to see in more detail what the functional consequences are of those variants and their influence on these genes in Parkinson's disease," said Bernabé Ignacio Bustos, Ph.D., a postdoctoral research fellow in the Lubbe laboratory and lead author of the study.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound - European Journal of Nuclear Medicine and Molecular ImagingPurpose Targeted α-therapy (TAT) for prostate-specific membrane antigen (PSMA) is a promising treatment for metastatic castration-resistant prostate cancer (CRPC). Astatine is an α-emitter (half-life=7.2 h) that can be produced by a 30-MeV cyclotron. This study evaluated the treatment effect of 211At-labeled PSMA compounds in mouse xenograft models. Methods Tumor xenograft models were established by subcutaneous transplantation of human prostate cancer cells (LNCaP) in NOD/SCID mouse. [211At]PSMA1, [211At]PSMA5, or [211At]PSMA6 was administered to LNCaP xenograft mice to evaluate biodistribution at 3 and 24 h. The treatment effect was evaluated by administering [211At]PSMA1 (0.40 ± 0.07 MBq), [211At]PSMA5 (0.39 ± 0.03 MBq), or saline. Histopathological evaluation was performed for the at-risk organs at 3 and 6 weeks after administration. Results [211At]PSMA5 resulted in higher tumor retention compared to [211At]PSMA1 and [211At]PSMA6 (30.6 ± 17.8, 12.4 ± 4.8, and 19.1 ± 4.5 %ID/g at 3 h versus 40.7 ± 2.6, 8.7 ± 3.5, and 18.1 ± 2.2%ID/g at 24 h, respectively), whereas kidney excretion was superior in [211At]PSMA1 compared to [211At]PSMA5 and [211At]PSMA6. An excellent treatment effect on tumor growth was observed after [211At]PSMA5 administration. [211At]PSMA1 also showed a substantial treatment effect; however, the tumor size was relatively larger compared to that with [211At]PSMA5. In the histopathological evaluation, regenerated tubules were detected in the kidneys at 3 and 6 weeks after the administration of [211At]PSMA5. Conclusion TAT using [211At]PSMA5 resulted in excellent tumor growth suppression with minimal side effects in the normal organs. [211At]PSMA5 should be considered a new possible TAT for metastatic CRPC, and translational prospective trials are warranted.
Weiterlesen »
Police hunt Burnley man who failed to turn up for courtCallum Parkinson failed to appear at court and now police are on the look out for him
Weiterlesen »
Ultrafast Electron Microscope Built to See Events at the NanoscaleA group of scientists from Nagoya University in Japan used a novel combination of technologies to investigate the principles of light–matter interaction in nanomaterials at the lowest and fastest levels.
Weiterlesen »
'Right out of the movies': Couple who tried to sell US nuclear submarine secrets to foreign country are jailedA judge describes the FBI sting operation that caught Jonathan and Diana Toebbe as reading 'like a crime novel or a movie script'.
Weiterlesen »
The battle for Disco Elysium's soul explodes with new allegations, and is heading to court'We think it's time people knew what has transpired,' say fired creative leads. Meanwhile, the company accuses them of toxic management.
Weiterlesen »